Antitumor properties of irinotecan-containing nanoparticles prepared using poly(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol)

Biological and Pharmaceutical Bulletin

Volumn 26, Issue 1, 2003, Pages 116-119

  Onishi, Hiraku ^a   Machida, Yoshiaki ^b   Machida, Yoshiharu ^a  

^a HOSHI UNIVERSITY   (Japan)

^b Hachioji Digestive Disease Hospital   (Japan)

Author keywords

Antitumor effect; Irinotecan; Nanoparticle; Plasma concentration; Poly(DL lactic acid); Poly(ethylene glycol) block poly(propylene glycol) block poly(ethylene glycol)

Indexed keywords

COPOLYMER; IRINOTECAN; MACROGOL DERIVATIVE; NANOPARTICLE; ORGANIC SOLVENT; POLY(ETHYLENE GLYCOL) BLOCK POLY(PROPYLENE GLYCOL) BLOCK POLY(ETHYLENE GLYCOL); POLYLACTIC ACID; UNCLASSIFIED DRUG; WATER; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; GROWTH INHIBITOR; LACTIC ACID DERIVATIVE; MICROSPHERE; POLY(LACTIC ACID ETHYLENE GLYCOL); POLY(LACTIC ACID-ETHYLENE GLYCOL);

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SYNTHESIS; EVAPORATION; MALE; NONHUMAN; PARTICLE SIZE; RAT; SARCOMA; TUMOR GROWTH; ANIMAL; BLOOD; DRUG DOSAGE FORM; DRUG SCREENING; METHODOLOGY; MOUSE; NANOTECHNOLOGY; SARCOMA 180; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DOSAGE FORMS; GROWTH INHIBITORS; LACTATES; MALE; MICE; MICROSPHERES; NANOTECHNOLOGY; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SARCOMA 180; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038382954     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.26.116     Document Type: Article

References (18)

1. Nagata H., J. Aichi Med Univ Assoc., 15, 683-699 (1987).
2. Kawato Y., Aonuma M., Hirota Y, Kuga H, Sato K., Cancer Res, 51, 4187-4191 (1991).
3. Okada K, Ando T., Antibiot Chemother., 9, 221-228 (1993).
4. Inaba M., Abstract of Research Works for the General Research A of Subject Number 05302061 with a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan, 1994, pp. 57-61.
5. Kaneda N., Nagata H., Furuta T., Yokokura T., Cancer Res., 50, 1715-1720 (1990).
6. Tsuruo T., Matsuzaki T., Matsushita M., Saito H., Yokokura T., Cancer Chemother. Pharmacol, 21, 71-74 (1988).
7. Nitta K., Yokokura T., Sawada S., Kunimoto T., Tanaka T., Uehara N., Baba H., Takeuchi M., Miyasaka T., Mutai M., Jpn. J Cancer Chemother, 14, 850-857 (1987).
8. Furuta T., Yokokura T., Mutai M., Jpn. J Cancer Chemother. 15, 2757-2760 (1988).
9. Furuta T, Yokokura T., Jpn. J Cancer Chemother, 15, 2757-2760 (1990).
10. Araki E., Ishikawa M., Iigo M., Koide T., Itabashi M., Hoshi A., Jpn. J. Cancer Res , 84, 697-702 (1993)
11. Takasuna K., Hagiwara T, Hirohashi M., Kato M., Nomura M, Nagai E., Yokoi T., Kamataki T., Cancer Res, 56, 3752-3757 (1996)
12. Mick R., Gupta E., Vokes E. E., Ratain M. J., J. Clin. Oncol., 14, 2012-2019 (1996).
13. Machida Y, Onishi H, Morikawa A., Machida Y., S.T.P Pharma Sci., 8, 175-181 (1998).
14. Machida Y., Onishi H., Kurita A., Hata H., Morikawa A, Machida Y., J. Control Release, 66, 159-175 (2000).
15. Yokoyama M., Drug Delivery System, 14, 449-457 (1999).
16. Dunn S. E., Coombes A. G. A., Garnett M. C., Davis S. S., Davies M. C., Illum L, J Control. Release, 44, 65-76 (1997).
17. Takakura Y., Takagi A, Hashida M., Sezaki H., Pharm. Res., 4, 293-300 (1987).
18. Matsumura Y., Maeda H, Cancer Res., 46, 6387-6392 (1986).